Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Foteini Strimenopoulou

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Statistical Applications in Genetics and Molecular Biology|March 4, 2008
Empirical Bayes logistic regressionFoteini Strimenopoulou, Philip J Brown
Journal of Biopharmaceutical Statistics|February 8, 2023
Recent Use of Pediatric Extrapolation in Pediatric Drug Development in USJingjing Ye, Vickie Zhang, Foteini Strimenopoulou, et al.
British Journal of Clinical Pharmacology|November 19, 2016
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasisSophie Glatt, Eric Helmer, Birgit Haier, et al.
Annals of the Rheumatic Diseases|June 10, 2019
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept studySophie Glatt, Peter C Taylor, Iain B McInnes, et al.
Ebiomedicine|August 28, 2018
Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942Gary Burgess, Malcolm Boyce, Margaret Jones, et al.
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Annals of the Rheumatic Diseases|December 25, 2017
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammationSophie Glatt, Dominique Baeten, Terry Baker, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Statistical Applications in Genetics and Molecular Biology|March 4, 2008
Empirical Bayes logistic regressionFoteini Strimenopoulou, Philip J Brown
Journal of Biopharmaceutical Statistics|February 8, 2023
Recent Use of Pediatric Extrapolation in Pediatric Drug Development in USJingjing Ye, Vickie Zhang, Foteini Strimenopoulou, et al.
British Journal of Clinical Pharmacology|November 19, 2016
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasisSophie Glatt, Eric Helmer, Birgit Haier, et al.
Annals of the Rheumatic Diseases|June 10, 2019
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept studySophie Glatt, Peter C Taylor, Iain B McInnes, et al.
Ebiomedicine|August 28, 2018
Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942Gary Burgess, Malcolm Boyce, Margaret Jones, et al.
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Annals of the Rheumatic Diseases|December 25, 2017
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammationSophie Glatt, Dominique Baeten, Terry Baker, et al.
Pageof 1